Shaken not stirred

OPEN ARCHIVE

Union Jack
Dannebrog

Shaken not stirred

Show simple item record

dc.contributor.author Valentin, Finn en_US
dc.contributor.author Dahlgren, Henrich en_US
dc.date.accessioned 2009-02-04T10:24:46Z
dc.date.available 2009-02-04T10:24:46Z
dc.date.issued 2007-12-13T00:00:00Z en_US
dc.identifier.isbn 9788791549205 en_US
dc.identifier.uri http://hdl.handle.net/10398/6776
dc.description.abstract Prior research has addressed the role of single large firms in Regional Innovation Systems (RIS), ascribing them the role of "flagships”, "hubs” etc. Less attention has been given to RIS dynamics set in motion when a flagship abruptly rearranges or ceases local operations, as is often the outcome when it is acquired by, or merged into, a larger multinational enterprise. The two flagships of the Swedish pharmaceutical industry – Pharmacia and Astra - shifted from domestic to multinational ownership in 1995 and 1998. We study consequences of this shift focusing on the following issues: i) Whether the shift in ownership brought about expansion or contraction of operations carried out internally by the two firms in Sweden. Observing notably declining activities in Pharmacia and expansion in Astra’s case we discuss control rights as a factor in national regulation affecting long-term strategising on part of key investors. ii) Whether the reduction of Pharmacia’s Swedish operations has been substituted by new firms derived from Pharmacia in the forms of divestments, spin-offs or startups. Identification of the founders of new bio-pharmaceutical firms reveals very little manager-to-founder migration out of Pharmacia, whereas considerably derived activity comes out of firms divested or spun-off while Pharmacia was still fully operative. iii) Whether the recombinatorial capacity of the innovation system in the Stockholm-Uppsala region plays a role in explaining the paucity of Pharmacia-derived start-ups. Compared to the Copenhagen region (the other major biotech concentration in 3 Scandinavia) Stockholm-Uppsala’s RIS is shown generally to have been notably less effective in mobilising industrial managerial talent for bio-entrepreneurship. To better understand this inter-regional divergence we model differences between the two RIS in the supply of venture capital to the financing rounds of young biotech start-ups. In RIS dynamics venture capital has the critical function of connecting managerial talent with entrepreneurial resources. For new bio-firms this particular RIS-function is shown to have performed significantly weaker in the Stockholm-Uppsala region as compared to the Copenhagen counterpart. This deficiency may be expected to rank importantly among causes for the comparatively lower incidence of manager-to-founder transitions amongst Stockholm-Uppsala’s new biopharmaceutical firms. en_US
dc.format.extent 38 s. en_US
dc.language eng en_US
dc.relation.ispartofseries Working paper;2007-04 en_US
dc.title Shaken not stirred en_US
dc.type wp en_US
dc.accessionstatus modt07dec13 nijemo en_US
dc.contributor.corporation Copenhagen Business School. CBS en_US
dc.contributor.department Research Centre on Biotech Business
dc.contributor.department Institut for Industriøkonomi og Virksomhedsstrategi en_US
dc.contributor.departmentshort CEBI en_US
dc.contributor.departmentshort BIOTECH
dc.contributor.departmentuk Research Centre on Biotech Business
dc.contributor.departmentuk Department of Industrial Economics & Strategy en_US
dc.contributor.departmentukshort BIOTECH
dc.contributor.departmentukshort IES en_US
dc.idnumber 9788791549205 en_US
dc.publisher.city København en_US
dc.publisher.year 2007 en_US
dc.title.subtitle Multinational takeovers in Sweden's pharmaceutical industry en_US


Creative Commons License This work is licensed under a Creative Commons License.

Files Size Format View
wp04-2007.pdf 245.9Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record